Tel-Aviv, Sept. 19th , 2019
eHealth Ventures (www.ehv.health), the leading Digital Health technological incubator in Israel, has announced the acceptance of its 9th portfolio company: Ophthalmic Sciences Ltd. (“OS”), developing a highly innovative product aimed at revolutionizing eye care through a proprietary ophthalmic diagnostic technology for screening and monitoring for Glaucoma.
Glaucoma is one of the leading causes for blindness in the world, and its key indicator is intra-ocular pressure (“IOP”). This pressure changes throughout the day, so optimal and customized treatment must be based on several pressure measurements each day. OS is developing a medical device used to diagnose and manage glaucoma treatment by simple, non-invasive and convenient home measurement of IOP.
The product is based on a mask resembling goggles and containing a tiny pump which produces controlled air pressure, with a micro-camera to capture vascular response in different parts of the eye. A dedicated algorithm calculates the IOP of the patient from the processed image, and the result is presented to the patient via his smartphone, sending the results to the cloud for monitoring and documentation.
The company is managed by Gabriel Dan and Noam Hadas, both talented and seasoned engineers and entrepreneurs with over 50 joint years of Medical Device development and commercialization expertise.
Talor Sax, CEO of eHealth Ventures:” We are happy to invest in our first Ophthalmic company. The sector is in need for innovative, home-based solutions and the use of Digital Health technologies can serve as a powerful driver for accuracy and accessibility of diagnostics in the field. Gabriel and Noam are highly experienced entrepreneurs and we are looking forward to a fruitful relationship and near-term success in development and clinical testing of the product, which is attracting a lot of interest from clinicians. This can be a game-changing solution”.
About eHealth Ventures:
eHealth Ventures is a multinational consortium of world-class medical organizations, industry leaders, and seasoned financial investors. Partners include Maccabi – Israel’s leading HMO, the Israeli Innovation Authority (IIA), Amgen – a global biotechnology leader, Medison Pharma – a leading Israeli pharmaceutical distributor and SCI – a major Chinese VC fund. eHV has reviewed over 950 projects and invested in 9 innovative companies.
Contact: Gabriel Dan, CEO – Ophthalmic Sciences Ltd.